Definium Therapeutics (NASDAQ:DFTX) Shares Down 7.9% – Time to Sell?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares fell 7.9% during trading on Monday . The stock traded as low as $41.25 and last traded at $41.38. Approximately 364,029 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 2,269,607 shares. The stock had previously closed at $44.91.

Analysts Set New Price Targets

DFTX has been the topic of several analyst reports. Canaccord Genuity Group set a $64.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Bank of America assumed coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price target on the stock. Finally, JonesTrading increased their target price on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $63.00.

Definium Therapeutics Stock Up 3.6%

The company’s 50-day moving average is $42.82 and its two-hundred day moving average is $28.26. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The company has a market cap of $6.02 billion, a P/E ratio of -13.06 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities analysts predict that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Activity

In other Definium Therapeutics news, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares in the company, valued at $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,096 shares of company stock worth $2,165,763 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System bought a new position in Definium Therapeutics in the 2nd quarter worth approximately $283,999,000. Seven Fleet Capital Management LP purchased a new stake in Definium Therapeutics during the second quarter valued at $6,992,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Definium Therapeutics during the 2nd quarter valued at about $1,592,000. Concurrent Investment Advisors LLC bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $943,000. Finally, AXQ Capital LP purchased a new position in Definium Therapeutics during the second quarter worth $585,000. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.